LSP's portfolio company EyeSense enters strategic partnership with Lee’s Pharmaceutical Holdings



Through the attached press release we are happy to announce the strategic partnership between our portfolio company EyeSense and Lee’s Pharmaceutical  (Lee’s PHARM” - Hong Kong Stock Exchange; Stock Code 950). By combining Lee’s PHARM’s strong presence in the dynamically growing Chinese and South Asian markets and Eyesense’s unique glucose sensing technology, the partners agreed to develop and commercialize a new continuous blood glucose monitoring system for diabetes patients. Lee’s PHARM acquired a minority equity stake in EyeSense and Powder Pharmaceuticals Inc., (“Powder”), an associated company of Lee’s PHARM, attained rights for the development and future commercialization of the device in China and other South Asian countries, except for Japan.
 
EyeSense’s continuous blood glucose monitoring (CGM) approach sets an important milestone in the diabetes field. The Company’s innovative and highly accurate device is based on a novel optical sensing technology and initial patient studies have yielded very promising data. Accuracy, reliability, and extended lifetime of the device will enable patients to significantly improve their disease management at reduced costs and high comfort. The company intends to launch the new device in 2016.
 
About LSP
LSP (Life Sciences Partners) is a leading independent European investment firm, providing financing for private and public life-science companies. Since the late 1980s, LSP’s management has invested in a large number of highly innovative enterprises, many of which have grown to become leaders of the global life-science industry. With over USD 1 billion of investment capital raised to date and offices in Amsterdam, Munich and Boston, LSP is one of Europe’s largest and most experienced specialist life-science investors. For more information, please visit www.lspvc.com.
 
About EyeSense AG
EyeSense™ AG is a venture-backed diagnostic device company based in Basel, Switzerland, and with operations near Frankfurt am Main, Germany. EyeSense was founded in 2006 as a spinout from Ciba Vision AG (a Novartis company), and develops diagnostic systems focusing on glucose testing for diabetic patients. EyeSense’s technology has the potential to grow the CGM market significantly and to allow CGM availability for a large portion of the diabetes population.In addition to glucose, the testing platform being developed by EyeSense has the potential to measure a broad variety of medical-relevant analytes in patients. See www.eyesense.com for more details.
 
For more information, please contact:
 
Dr. Jörg Neermann, Partner LSP
Tel: +49 89 330666 0
warreznaa@yfcip.pbz
www.lspvc.com
 
« back to overview
Follow us

LSP's portfolio company EyeSense enters strategic partnership with Lee’s Pharmaceutical Holdings



Through the attached press release we are happy to announce the strategic partnership between our portfolio company EyeSense and Lee’s Pharmaceutical  (Lee’s PHARM” - Hong Kong Stock Exchange; Stock Code 950). By combining Lee’s PHARM’s strong presence in the dynamically growing Chinese and South Asian markets and Eyesense’s unique glucose sensing technology, the partners agreed to develop and commercialize a new continuous blood glucose monitoring system for diabetes patients. Lee’s PHARM acquired a minority equity stake in EyeSense and Powder Pharmaceuticals Inc., (“Powder”), an associated company of Lee’s PHARM, attained rights for the development and future commercialization of the device in China and other South Asian countries, except for Japan.
 
EyeSense’s continuous blood glucose monitoring (CGM) approach sets an important milestone in the diabetes field. The Company’s innovative and highly accurate device is based on a novel optical sensing technology and initial patient studies have yielded very promising data. Accuracy, reliability, and extended lifetime of the device will enable patients to significantly improve their disease management at reduced costs and high comfort. The company intends to launch the new device in 2016.
 
About LSP
LSP (Life Sciences Partners) is a leading independent European investment firm, providing financing for private and public life-science companies. Since the late 1980s, LSP’s management has invested in a large number of highly innovative enterprises, many of which have grown to become leaders of the global life-science industry. With over USD 1 billion of investment capital raised to date and offices in Amsterdam, Munich and Boston, LSP is one of Europe’s largest and most experienced specialist life-science investors. For more information, please visit www.lspvc.com.
 
About EyeSense AG
EyeSense™ AG is a venture-backed diagnostic device company based in Basel, Switzerland, and with operations near Frankfurt am Main, Germany. EyeSense was founded in 2006 as a spinout from Ciba Vision AG (a Novartis company), and develops diagnostic systems focusing on glucose testing for diabetic patients. EyeSense’s technology has the potential to grow the CGM market significantly and to allow CGM availability for a large portion of the diabetes population.In addition to glucose, the testing platform being developed by EyeSense has the potential to measure a broad variety of medical-relevant analytes in patients. See www.eyesense.com for more details.
 
For more information, please contact:
 
Dr. Jörg Neermann, Partner LSP
Tel: +49 89 330666 0
warreznaa@yfcip.pbz
www.lspvc.com
 
« back to overview